Regeneron announced plans to seek regulatory approval after publication of New England Journal of Medicine data showing a gene therapy produced significant hearing improvement in nearly a dozen children with a rare genetic deafness. The trial data, presented in NEJM, reported measurable auditory gains and safety findings that the company says support an approval filing. Regeneron will now prepare regulatory dossiers and engage with agencies to pursue labeling and access for the pediatric population.